Skip to content

Biohaven BHVN Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$3.49M-1,155%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
-$17.22M-196%
uniQure logo
uniQureQURE
$3.9M+423%
Roivant Sciences logo
Roivant SciencesROIV
$63.23M
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-$10.79M+8.7%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$37.48M-93.5%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's change in accrued liabilities?
Biohaven (BHVN) reported change in accrued liabilities of -$64.41M in Q1 2026.
How has Biohaven's change in accrued liabilities changed year-over-year?
Biohaven's change in accrued liabilities decreased by 2415.4% year-over-year, from $2.78M to -$64.41M.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.